Abstract Right ventricular hypertrophy (RVH) and RV failure contribute to morbidity and mortality in pulmonary arterial hypertension (PAH). The cause of RV dysfunction and the feasibility of therapeutically targeting the RV are uncertain. We hypothesized that RV dysfunction and electrical remodeling in RVH result, in part, from a glycolytic shift in the myocyte, caused by activation of pyruvate dehydrogenase kinase (PDK). We studied two complementary rat models: RVH+PAH (induced by monocrotaline) and RVH+without PAH (induced by pulmonary artery banding (PAB)). Monocrotaline RVH reduced RV O 2 -consumption and enhanced glycolysis. RV 2-fluoro-2-deoxy-glucose uptake, Glut-1 expression, and pyruvate dehydrogenase phosphorylation increased in monocrotaline RVH. The RV monophasic action potential duration and QT c interval were prolonged due to decreased expression of repolarizing voltage-gated K + channels (Kv1.5, Kv4.2). In the RV working heart model, the PDK inhibitor, dichloroacetate, acutely increased glucose oxidation and cardiac work in monocrotaline RVH. Chronic dichloroacetate therapy improved RV repolarization and RV function in vivo and in the RV Langendorff model. In PAB-induced RVH, a similar reduction in cardiac output and glycolytic shift occurred and it too improved with dichloroacetate. In PAB-RVH, the benefit of dichloroacetate on cardiac output was approximately 1/3 that in monocrotaline RVH. The larger effects in monocrotaline RVH likely reflect dichloroacetate's dual metabolic benefits in that model: regression of vascular disease and direct effects on the RV. Reduction in RV function and electrical remodeling in two models of RVH relevant to human disease (PAH and pulmonic stenosis) result, in part, from a PDK-mediated glycolytic shift in the RV. PDK inhibition partially restores RV function and regresses RVH by restoring RV repolarization and enhancing glucose oxidation. Recognition that a PDKmediated metabolic shift contributes to contractile and ionic dysfunction in RVH offers insight into the pathophysiology and treatment of RVH.
Introduction
Pulmonary arterial hypertension (PAH) is a lethal syndrome caused by arterial obstruction related to excessive proliferation and impaired apoptosis of pulmonary artery smooth muscle cells (PASMC), endothelial dysfunction, inflammation, and excessive vasoconstriction [1] . While pulmonary Electronic supplementary material The online version of this article (doi:10.1007/s00109-009-0524-6) contains supplementary material, which is available to authorized users. vascular disease is the obvious primary pathologic focus, right ventricular hypertrophy (RVH) and RV contractile dysfunction are major determinants of prognosis in PAH [2] . Some studies have shown that PAH induced by monocrotaline in animal models is associated with RV dysfunction [3, 4] . However, little is known about the specific mechanisms underlying RV dysfunction in PAH. Moreover, it is unclear whether therapies that target the RV (alone or in combination with the pulmonary vasculature) might be beneficial.
In RVH, prolongation of action potential duration (APD) and the QT interval corrected for heart rate (QTc) have been reported [5] , and an accompanying downregulation of repolarizing Kv channels has been noted, namely Kv1.2, 1.5, 2.1, 4.2, and 4.3 [6, 7] . QTc prolongation is also noted in humans with PAH [8] . However, the cause, consequences, and reversibility of this electrical remodeling in RVH are unclear. Monophasic APD (MAPD) prolongation can promote arrhythmia [9] and increase cytosolic Ca 2+ in cardiac myocytes [10] . The duration and positivity of the action potential's plateau phase is also an important determinant of cardiac contractility [11] . Impaired early repolarization causes dysynchrony of the release of Ca 2+ from the sarcoplasmic reticulum and decreases contractility; conversely, therapies that restore normal repolarization are predicted to enhance contractility by improving excitationcontraction coupling [12] . A clue to the cause of electrical remodeling in RVH comes from positron emission tomography (PET) studies of small groups of PAH patients. Increased 2-fluoro-2-deoxy-D-glucose (FDG) uptake occurs in the RV in PAH [13, 14] . This suggests the RV may be glycolytic; moreover, mild hyperoxia can improve experimental RVH, again suggesting that glucose oxidation may be impaired in RVH [15] . However, the cause of the increased FDG uptake and its relevance to the pathophysiology and treatment of RVH are unknown.
Interestingly, the PASMC [1] and endothelial cells [16] in PAH manifest a metabolic shift, characterized by enhanced glycolysis. Moreover, expression of Kv1.5 is downregulated in PAH PASMC, leading to membrane depolarization and calcium overload. Restoration of oxidative phosphorylation, using a prototypic pyruvate dehydrogenase kinase (PDK) inhibitor, dichloroacetate [17] , decreases the severity of pulmonary hypertension and regresses RVH in multiple models of experimental PAH [1, 18] . It does so, in part, by restoring K + channel expression/function, indicating a link between the metabolic state and the electrical remodeling in PASMC. In the vasculature, changes in metabolism appear to initiate upregulation of transcription factors that decrease Kv channel expression, including nuclear factor-activating Tcells (NFAT) [19] and hypoxia-inducible factor [1] .
In left ventricular hypertrophy (LVH), glycolytic flux is increased and predominates over glucose oxidation [20] . Dichloroacetate doubles glucose oxidation and improves LV function in an LVH model challenged with ischemiareperfusion [21] . Dichloroacetate also restores I to in a rat myocardial infarction model [22] . These findings support a link between impaired aerobic metabolism, depressed Kv channel expression, and impaired contractile function in the LV. The RV in PAH has similarities to hibernating LV myocardium in coronary artery disease patients. Recent data suggests that right coronary artery blood flow is reduced in PAH patients with severe RVH [2] , suggesting chronic ischemia as a potential initiating stimulus for the proposed metabolic shift in severe RVH.
We used two different models of RVH to investigate whether the beneficial effects of PDK inhibition are secondary to reduced PAH, direct effects on the RV myocardium, or a combination of the two. In the monocrotaline model, there is an intrinsic coupling between severity of RVH and severity of the pulmonary vascular disease, while pulmonary artery banding (PAB) results in RVH secondary to pure pressure overload. We simultaneously measured MAPD and RV contractility in an RV Langendorff model and assessed RV work and metabolism (using a dual isotope technique) in a working RV model to test the hypothesis that, in RVH, reduced RV function reflects two consequences of PDK activation: increased glycolysis and electrical remodeling that impairs early repolarization. A corollary of the hypothesis is that the PDK inhibitor dichloroacetate should restore repolarization and improve RV function by increasing glucose oxidation in both RVH models.
Methods
The authors had full access to the data and take full responsibility for their integrity. All authors have read and agreed to the manuscript as written.
Experimental protocols
The University of Chicago Institutional Animal Care and Use Committee approved all protocols. In the monocrotaline model, adult male Sprague-Dawley rats weighing 260-280 g were randomized to the following groups: control, dichloroacetate, monocrotaline, and monocrotaline + dichloroacetate. A single subcutaneous injection of monocrotaline (60 mg/kg, Sigma, St. Louis, MO, USA) produced severe PAH and RVH at 1 month. The water for the dichloroacetate and monocrotaline+dichloroacetate groups contained dichloroacetate 0.75 g/L, pH 7.0 (Sigma, St. Louis, MO, USA), and rats consumed an estimated daily dose of 70 mg/kg. Dichloroacetate therapy started on day 10 post-monocrotaline, at which time, PAH is established [18] .
A pressure-overload RVH model was created by PAB. Penicillin G (600,000 U) was administered preoperatively. The rat was anesthetized with 3% isoflurane and then intubated. A median sternotomy was performed, and the PA was dissected free from the aorta and left atrium. A silk suture was placed around the PA, and a loose knot formed. A 16-gauge needle was inserted through the knot, parallel to the PA. The suture was tied tightly, and the needle was withdrawn, creating a stenosis equal to the needle's diameter (approximately 1.6 mm). After PAB, the thorax was closed. Pain relief was achieved using buprenorphine (15 µg/kg sc). The PAB protocol included four groups: sham, dichloroacetate, PAB, and PAB+dichloroacetate (0.75 g/L in the drinking water). Dichloroacetate therapy started on the same day as PAB surgery. The hearts were studied 7 weeks after PAB. Sham and sham+dichloroace-tate groups had gained 316±19 and 318±17 g body weight (n=6-7, P>0.05) 7 weeks after sham surgery. Although the increase of the body weight in PAB and PAB+dichloroa-cetate groups was less than the increase in sham and sham+ dichloroacetate groups due to the surgery, PAB and PAB+ dichloroacetate groups still had gained 268±16 and 249± 14 g body weight, respectively. There were no differences in weight gain between the two groups (n=6-7, P>0.05).
Echocardiography
Doppler, 2D, and M-mode echo was applied to measure the PA acceleration time (PAAT), diastolic thickness, and systolic thickness of the right ventricular free wall thickness (RVFW) (see Methods in on-line Supplement).
Positron emission tomography (PET)
Glucose uptake was imaged in vivo in rats anesthetized using isoflurane gas anesthesia (2% in oxygen) using FDG as a radiotracer. PET imaging was performed using a Triumph PET/SPECT/CT system (GE Healthcare, Northridge, CA, USA). Rats fasted overnight and were given a sucrose load 30 min before FDG injection (20×45 mg sucrose pellets, Bilaney Consultants, NJ, USA). Images were acquired 20 min after FDG injection. To provide anatomical references, the rat thorax was first imaged using micro-CT followed by a 60-min PET data acquisition. Images are shown using a pseudo color map (red indicates high and green indicates low glucose uptake). Data were analyzed by manual segmentation of the LV and RV free walls of the 3D PET image dataset.
Catheterization A Millar pressure catheter (Millar Instruments, Inc., Houston, TX, USA) was used to measure RV systolic pressure (RVSP) and PA pressure (PAP) in the PAB model. The apex of RV was punctured with a 26-gauge needle, and the catheter was threaded through it into the RV and then advanced across the PA banding site to measure PAP. Pressure was recorded by using a PowerLab data acquisition module (ADInstruments, Colorado Springs, CO, USA).
RV Langendorff perfusion and measurement of MAPD Rats were anesthetized with isoflurane, and hearts were excised and perfused with a saline solution for 1-2 min at 25°C and then mounted on a Langendorff perfusion apparatus for retrograde aortic perfusion with oxygenated KrebsHenseleit buffer (95% O 2 +5% CO 2 ) at a constant pressure of 75-85 cm H 2 O (37°C). The PO 2 in the solution exceeded 560 mmHg in all experiments. The AV node was ablated, and hearts were paced at a cycle length of 200 ms. Hearts stabilized for 10-20 min and then RVSP was measured, as described [18] . RV monophasic action potentials were recorded by placing Teflon-coated, 0.25 mm silver electrodes gently on the RV [23] . The signals were recorded using PowerLab and analyzed using Chart V 5.5.6. MAPD was measured as the time to achieve 20% (MAPD20) and 90% (MAPD90) of complete repolarization [23] .
Measurement of RVH RVH was measured as the ratio of RV/(LV+septum) weight.
O 2 -Consumption RV respiration was measured by highresolution respirometry (Oroboros, Innsbruck, Austria). Briefly, a section of RV (140 mg) was minced and added to a respirometry chamber containing 2 ml saline at 37°C. The O 2 concentration was recorded for 20 min, and peak O 2 -consumption was measured using DatLab (Oroboros).
Simultaneous measurement of metabolism and function in the RV working heart model In a separate set of experiments, an isolated working heart model was used to simultaneously measure metabolism and RV work (heart rate X RVSP). The heart was rapidly excised and subsequently mounted on an aortic perfusion cannula for about 10 min. The pulmonary veins, main PA, and superior vena cava were isolated and cannulated. The inferior vena cava was isolated and ligated. To initiate flow to the RV and LV, perfusate was delivered to the superior vena cava and left atria cannulae at a constant preload (45 and 115 mmHg, respectively). Hearts worked against an 80-mmHg aortic afterload and a 45-mmHg PA afterload. Cardiac output was measured with Transonic ultrasound flow probes in the afterload lines, and cardiac work was calculated as the product of systolic pressure and cardiac output, as described [24] . Glycolysis and glucose oxidation were measured by perfusing hearts with Krebs-Henseleit buffer containing 11 mM [5-3H/U-14C] glucose, 0.5 mM lactate, 1.2 mM palmitate, 3% albumin, and 100 U/ml insulin, as previously described [25] . The effect of dichloroacetate on glucose oxidation and cardiac function was evaluated by quantitative collection of 3 H 2 O (glycolysis) and 14 CO 2 (glucose oxidation), at 10-min intervals after adding 1 mM dichloroacetate to the perfusate.
Statistics Values were expressed as mean± SEM. The differences among the four groups were assessed by oneway analysis of variance with post hoc testing using the Fisher probable least significant differences test. A paired t test was used for assessing the effect of dichloroacetate at baseline vs 40 min of perfusion. A value of P<0.05 was considered statistically significant.
Electrocardiograms, qRT-PCR, immunofluorescence, immunoblotting, histology, and thermodilution cardiac output See on-line Supplement.
Results

Hemodynamics, histology, and cardiac function
Four weeks after monocrotaline, pulmonary hypertension was evident. The PAAT was shortened in monocrotaline vs control rats and was improved in the dichloroacetate+ monocrotaline group (12.4±0.3, 35.0±0.7 vs 20.6±2.7 ms, respectively; n=6-12/group, P<0.001, Fig. 1a ). Monocrotaline increased the RV/(LV+septum) weight ratio vs control, and this was reduced in the dichloroacetate+ monocrotaline group (0.61±0.04, 0.27±0.01 vs 0.39± 0.04, respectively n=10-11, P<0.05; Fig. 1b ). Dichloroacetate also reversed monocrotaline-induced hypertrophy of individual RV myocytes on histology (Fig. 1c) . Increased RVFW thickness in monocrotaline vs control was also reduced in the dichloroacetate+monocrotaline group (1.67± 0.06, 0.95±0.02 vs 1.37±0.10 mm, respectively; n=6-13, P< 0.001, Fig. 1d ). RV systolic function was reduced in monocrotaline vs control rats, suggesting impaired RV contractility. Compared to control, RVFW systolic shortening was significantly reduced by monocrotaline and was improved by dichloroacetate (85±10%, 19±10% vs 65± 14%, respectively, n=3, P<0.05, Fig. 1e ). In the Langendorff model, developed RVSP was significantly elevated in monocrotaline vs control and was decreased in the dichloroacetate+monocrotaline group (63±7, 31±3, 43±3 mmHg, respectively, n=8-9, P<0.05, Fig. 1f ). In vivo, thermodilution CO was reduced in monocrotaline vs control (58.3±4.9 vs 154.2±16.2 ml/min, n=6, P<0.001, Fig. 1g ) and this improved in the dichloroacetate+monocrotaline group to 124.6±15.7 ml/min, n=6, P<0.005). Dichloroacetate did not cause hemodynamic or histological changes in control rats ( Fig. 1 ).
Metabolic changes in RVH
In the RV working heart model, cardiac work tended to increase during a 40-min period of observation. However, the only significant increase in cardiac work occurred in monocrotaline hearts that received dichloroacetate (1 mM) in the perfusate (n=4-5, p=0.05; Fig. 2a) .
Basal rates of glucose oxidation did not differ among the groups (Fig. 2b) . However, glycolysis rates were increased in monocrotaline vs control (4,025±611 vs 1,872±430 nmol/min×g dry wt, n=5, respectively. P< 0.05. Fig. 2c ). Addition of 1 mM dichloroacetate to the perfusate increased glucose oxidation in monocrotaline RVH from 772 ± 323 to 3,426 ± 312 nmol/min × g dry weight (n=5, P<0.001, Fig. 2b ), with no change in glycolytic rates (Fig. 2c) .
RV O 2 -consumption was reduced in monocrotaline vs control, and this was restored in monocrotaline+dichlor-oacetate (148±27, 277±27 vs 230±22 pmol/s×ml, respectively, n=6-7, P<0.05, Fig. 3a, b) . Consistent with the increased glycolysis, FDG uptake was elevated in RV of monocrotaline rats (Fig. 3c) . The RV/LV FDG uptake was increased in monocrotaline vs control (1.50±0.41 vs 0.46± 0.03, n=7-9, P<0.05, Fig. 3d ). Dichloroacetate tended to reduce FDG uptake ratio to 1.19±0.34 (n=11, P=NS)
Immunostaining showed qualitatively greater expression of the cardiac glucose transporter Glut1 [26] in monocrotalineinduced RVH, both in the cytosol and at the plasma membrane (where it colocalized with dystrophin). Glut1 expression was decreased toward normal in the monocrotaline+dichloroacetate group (Fig. 4a) . Consistent with the immunofluorescence, monocrotaline RVH was accompanied by a threefold increase expression of Glut1 mRNA (n=6, respectively, P<0.001, Fig. 4b ). Dichloroacetate reduced Glut1 mRNA by 43% (n=6, P<0.05 vs monocrotaline). Glut1 protein expression was also increased in monocrotaline group and decreased in the monocrotaline+dichloroace-tate group (n=4/group; P<0.05, Fig. 4c ).
To confirm whether the effect of dichloroacetate was mediated via PDK inhibition, we measure pyruvate dehydrogenase (PDH) phosphorylation. Phosphorylated PDH increased 2.5-fold in the monocrotaline group, and this decreased in monocrotaline+dichloroacetate group (n=7-8, P<0.05, Fig. 4d ). Dichloroacetate did not change Glut1 and PDH expression in control rats (data not shown).
Expression of both Glut1 and phosphorylated PDH did not change in LV in either monocrotaline or monocrotaline+ dichloroacetate groups (see Supplemental Fig. 1 ).
Electrical remodeling in RVH in the monocrotaline model
The time to achieve 20%and 90% of complete repolarization (MAPD20and MAPD90) in the RV were significantly increased in monocrotaline vs control (Fig. 5a-c) . Dichloroacetate shortened MAPD20 nearly to the control levels. To determine whether dichloroacetate acutely changes MAPD, 1 mM dichloroacetate was added to the perfusate. MAPD did not change within 50 min (n=2, P=NS, see Supplemental Fig. 2 ), suggesting that shortened MAPD in monocrotaline+dichloroacetate group is more likely due to the documented re-expression of Kv channels following chronic in vivo dichloroacetate treatment (Fig. 6) than to an acute effect of dichloroacetate on channel activity.
Consistent with the prolongation of MAPD, the QTc was prolonged in monocrotaline vs control groups and was normalized in the monocrotaline+dichloroacetate group (n=6, P<0.05, Fig. 5d , e). Dichloroacetate had no effect on MAPD or QTc interval in normal rats (Fig. 5) .
Expression of Kv1.2, Kv1.5, and Kv4.2 channel mRNA in the RV was downregulated in monocrotaline vs control groups (n=6, P<0.01, Fig. 6a-c ) and was partially restored by dichloroacetate. Kv1.4 and Kv2.1 mRNA did not change among the groups (n=4, P>0.05, Supplemental  Fig. 3) . At the protein level, Kv1.2, Kv1.5, and Kv4.2 expression was also significantly reduced in monocrotaline vs control groups (n =3-7, P < 0.05, Fig. 6d-f) . The expression of Kv1. Fig. 6e ).
RVH induced by pulmonary artery banding
In order to distinguish whether dichloroacetate's effects on RV function and hypertrophy reflected direct effects on the RV, independent of effects on the pulmonary vasculature, we used the PAB model. Histological study 7 weeks following PAB, showed RV myocyte hypertrophy in the PAB group, and this was partially reversed by concomitant dichloroacetate therapy (Fig. 7a) . The RVSP in RVH induced by PAB was reduced by dichloroacetate (23±2, 57±5, and 45±4 mmHg, respectively, n=3-4, P<0.05, Fig. 7b) . Likewise, the peak pressure gradient between the pulmonary artery and RV pressure was significantly reduced by dichloroacetate (Fig. 7b) . Dichloroacetate improved RVFW systolic thickening (control, 74±8%; PAB, 30±3%; PAB+dichloroacetate, 54±6%; n=3-14, P<0.05, Fig. 7c ). The CO, which was reduced in PAB group vs control, was partially restored in the PAB+ dichloroacetate group (177±11, 108±10, and 135±10 ml/ min, respectively, n=4-9, P<0.05, Fig. 7d ).
Similar to the monocrotaline model, hypertrophied RV myocytes in the PAB model had greater Glut1 expression than control RV myocytes, and chronic dichloroacetate therapy normalized both RV myocyte size and Glut1 expression (Fig. 8a) .
The reduced RV O 2 -consumption in PAB relative to control was restored in the PAB+dichloroacetate group (296±23, 208±19 vs 309±33 pmol/s×ml, n=6-7, P<0.05, Fig. 8b ), consistent with a dichloroacetate-mediated increase in glucose oxidation.
Discussion
RV function is a major determinant of functional class and survival in pulmonary hypertension [2] , heart failure, and many forms of congenital heart disease. In this study, we show that the hypertrophied RV undergoes a metabolic shift resulting in decreased RV function (Fig. 1e, g ). Furthermore, we demonstrated that the hypertrophied RV is associated with "electrical remodeling", which we define as the changes in cardiac depolarization or repolarization which occur in disease as a consequence of altered expression or function of ion channels in the cardiac myocyte (Figs. 5 and 6 ). Specifically, there is increased glycolysis in RVH (Fig. 2c) as evidence by increased FDG uptake on PET scans in vivo (Fig. 3c, d ) and elevated Glut1 expression with an increased PDH phosphorylation (Fig. 4) . Likewise, RVH and RV dysfunction induced by PAB are also associated with the reduced oxidative metabolism and increased Glut1 expression (Figs. 7 and 8) . In an RV working heart model, we show that enhancing glucose oxidation improves RV function in RVH (Fig. 2) . Dichloroacetate accomplished this increase in glucose oxidation by reversing the pathological phosphorylation of PDH that occurs in RVH (Figs. 4d and 8b) . Interestingly, dichloroacetate did not decrease glycolysis in RVH (Fig. 2c) . This may be related to the large increase in glucose oxidation seen in the dichloroacetate-treated hearts, which would result in a lowering of cytosolic pyruvate. A decrease in pyruvate, which is an end product of glycolysis, would stimulate a homeostatic increase in glycolysis to maintain glycolytic flux. Regardless, the large increase in glucose oxidation with dichloroacetate resulted in an improved coupling between glycolysis and glucose oxidation (Figs. 2b, c) . In addition, the electrical remodeling is largely reversed by dichloroacetate (Figs. 5 and 6 ), indicating that, like the cardiac dysfunction, the electrical remodeling is metabolically mediated. While prior research has shown downregulation of Kv channels in experimental RVH [5, 27, 28] and two observational studies have identified enhanced FDG uptake in the RV of patients with pulmonary hypertension [13, 14] , our report is the first to link these metabolic and ionic abnormalities by identifying PDK activation as a reversible cause of both abnormalities. A major strength of this research is the use of two models of RVH-one caused by pulmonary hypertension (analogous to human PAH) and one which is caused by PAB (a model of pulmonic stenosis) in the absence of pulmonary vascular disease.
We have previously shown that there is a metabolic shift in the pulmonary vasculature in PAH, and marked improvements in PAH can be seen when PDK is inhibited by dichloroacetate. However, since observational studies had reported increased glucose uptake in the RV of PAH patients [13, 14] , we hypothesized that the hypertrophied RV myocardium could exhibit a metabolic shift similar to what we had seen in the pulmonary vasculature [18] . We therefore comprehensively studied the metabolism of the hypertrophied RV.
A key finding of our study is the documentation of increased glycolysis in RVH (Fig. 2c) . These metabolic measurements are reinforced by the findings of increased expression of Glut-1 (Figs. 4b, c, and 8a) (Fig. 3c, d ), reminiscent of hibernating myocardium seen in patients with chronic left ventricular ischemia due to coronary artery disease. Increased expression of glut1 is associated with a tendency of this transporter protein to localize to the plasmalemma (indicating that it is active; Figs. 4a and 8a ). This study offers three new observations that have mechanistic and therapeutic relevance to RVH and which are consistent with the interpretation that the glycolytic metabolic shift is causally related to the changes in RV function and electrophysiology. We show that the metabolic abnormality in RVH:
1. Contributes substantially to both the RV dysfunction and the electrical remodeling; 2. Reflects PDK activation, PDH phosphorylation, and a resulting increase in glycolysis;
3. Is reversible being significantly ameliorated by the PDK inhibitor, dichloroacetate.
There is precedent for the benefits of dichloroacetate on RV function. Nagendran et al. used a Langendorff perfusion system to show improved right ventricular inotropy when rats with MCT-induced RVH are treated with dichloroacetate [29] . They showed that dichloroacetate "reversed both the phenylephrine-induced mitochondrial hyperpolarization and nuclear factor of activated T lymphocytes (NFAT) activation". They did not measure RV function in vivo or directly measure RV metabolism. Thus, while our study is consistent with theirs (suggesting a benefit for dichloroacetate in RVH), the two studies examine different mechanisms. Their work suggest a potential mechanism for the intersection between metabolism and electrical remodeling, in that changes in metabolism may ultimately lead to and dystrophin (red) in RV shows that more Glut1 is expressed at the myocyte membrane in RVH. b, c Glut1 mRNA and protein levels are significantly increased in RVH, and DCA normalizes expression. d Increased phosphorylation of PDH in RVH is reduced by dichloroacetate altered cardiac repolarization through a transcriptional mechanism that is regulated by NFAT. The use of the PAB model, which induces RVH and RV dysfunction independent of pulmonary vascular disease, allowed identification of direct beneficial effects of dichloroacetate on the RV. The observation that dichloroacetate was also beneficial in the PAB model (albeit less so than in the monocrotaline model), indicates that PDK inhibition by dichloroacetate can indeed improve RV function and reduce RVH by directly acting on the RV. In the monocrotaline model, dichloroacetate caused a 43% increase in CO, whereas in PAB, dichloroacetate increased CO by a smaller amount (16%, Fig. 8c ). It is not surprising that dichloroacetate has a larger benefit on RV function and RVH in the monocrotaline-PAH model since it exerts two complementary benefits in this model (reducing afterload through remodeling of the pulmonary vasculature and directly acting on the RV). Whereas, in the PAB model, the RV benefits are exclusively mediated via direct improvement in RV function, independent of any reduction of PA stenosis or pulmonary vascular resistance.
A number of technical innovations make our conclusion robust. The use of an RV Langendorff model (Fig. 1f) demonstrated the positive effects of dichloroacetate on RV function, independent of afterload, and also allowed simultaneous measurement of electrical function. The use of an RV working heart model and the dual isotope technique (Fig. 2) allowed simultaneous measurement of RV work and metabolism in response to dichloroacetate (at constant load). These models showed the increased glycolysis in monocrotaline-induced RVH is associated with reduced RV function and show that dichloroacetate's ability to increase contractility (i.e., increased RV work at a constant load, Fig. 2 ), is associated with increasing glucose oxidation. Finally, the use of high fidelity catheterization and PET scanning confirmed that the hemodynamic and biochemical changes detected in isolated organs/tissues reflected the physiology in vivo. Dichloroacetate improves metabolism in hypertrophied hearts Our findings suggest that the hypertrophied RV is an example of hibernation, meaning the RV is viable but its function is depressed. Depressed RV function in both models results in part from PDH inhibition, caused by PDK-mediated phosphorylation. The metabolic shift to glycolysis appears to be responsible for much of the observed RV dysfunction, and neither the metabolic nor the functional impairment occur in the LV (Fig. 3c and  supplemental Fig. 1 ).
PDK is a key regulator of glucose oxidation. Activated PDK phosphorylates and inhibits PDH (Fig. 4d) , blocking the entry of pyruvate into the mitochondria, and inhibiting formation of acetyl CoA and slows the Krebs' cycle [30] . In contrast to the normal RV, which can vary its substrate utilization from fatty acids to glucose as needed, RVH is associated with a persistent reliance on glucose metabolism [27] . Dichloroacetate, a prototypic inhibitor of PDK, activates PDH, thereby increasing acetyl coenzyme A and enhancing Krebs' cycle [31] . The 14 C-glucose technique [25] showed that dichloroacetate rapidly increases glucose oxidation and concordantly enhances RV function (Fig. 2) which, in light of the constant afterload in this model, is consistent with an increase in contractility. Dichloroacetate's ability to increase O 2 consumption (by enhancing glucose oxidation) was evident in both the monocrotaline and PAB models (Figs. 3a and 8b) . The relatively greater increase in glucose oxidation relative to glycolysis caused by dichloroacetate reflects better coupling and would be predicted to reduce lactate and proton production. This has the potential to increase cardiac efficiency, since less energy is used to correct this ionic imbalance.
The beneficial effects of chronic dichloroacetate likely relate both to the enhanced myocardial energetics that occurs when oxidative metabolism is enhanced and the restoration of Kv channel expression. In the working heart model, dichloroacetate rapidly improves RV function (Fig. 2a) . This improvement is too rapid to attribute to transcriptional restoration of Kv expression. We also show that dichloroacetate does not acutely shorten MAPDSupplemental Fig. 2) . Moreover, expression of the Glut1 transporter was also normalized by dichloroacetate in both models (Figs. 4a-c and 8a) . We believe that the upregulated Glut1 and impaired oxygen consumption in RVH reflect the need to increase glucose import in RVH to compensate for Published evidence for impaired metabolism in RVH is limited. However, a proteomic study of monocrotalineinduced RVH found a pattern of enzyme expression consistent with impaired oxidative metabolism, including downregulation of PDH (subunit beta E1), isocitrate dehydrogenase, succinyl coenzyme A ligase, NADH dehydrogenase, ubiquinol-cytochrome C reductase, and propionyl coenzyme A carboxylase [32] . We noted a similar reversible mitochondrial metabolic abnormality in the pulmonary vasculature in PAH and in human cancers [1, 19] . In both cases, these abnormalities are initiated and maintained, in part, by pathological PDK activation and in both cases, several weeks of dichloroacetate therapy is beneficial, regressing vascular obstruction in PAH [1] and stopping tumor growth in a xenotransplantation model of human lung cancer [19] . Similar benefits of PDK inhibition have been reported in experimental LVH [21, 33] and myocardial infarction [22] , conditions associated with enhanced glycolysis [21, 33] .
Dichloroacetate and electrical remodeling in RVH Cellular electrophysiological studies have shown that repolarization abnormalities noted on EKG in animals and humans with ventricular hypertrophy are caused by depression of K + currents [34] . It is an underappreciated fact that patients with RVH have mild prolongation of the QTc interval, particularly on right-sided leads [8] . A decrease in the I Kr in RVH appears to explain the prolongation of MAPD [28] . In the present study, multiple Kv channels including Kv1.2, Kv1.5, and Kv4.2 were downregulated in RVH, and this was accompanied by the prolongation of MAPD and the QTc interval. Inhibition of repolarizing K + currents and MAPD prolongation likely add to the negative inotropic effects of glycolytic metabolism and further reduce RV contractile function [10] (Fig. 8d) . Conversely, dichloroacetate's beneficial electrical effects are, at least in part, due to increased expression of several repolarizing Kv channels, including Kv4.2 and Kv 1.5 (Fig. 6b, c, e, f) . Dichloroacetate's effect in shortening MAPD20 may relate to its ability to increase expression of both Kv4.2 and Kv1.5, which have the properties of fast activation [6] . Acutely, application of dichloroacetate does not shorten MAPD, consistent with the dichloroacetate's effects on MAPD relating to re-expression of Kv channels, rather than enhanced channel activation (Supplemental Fig. 2 ). This suggests that the changes in mitochondrial metabolism induced by PDK contribute significantly to the electrical remodeling in RVH induced by PAH. Consistent with our findings, in a patch clamp of surviving cardiomyocytes from infarcted rat heart, dichloroacetate (1.5 mM) increases the depressed I to current density; whereas 3-bromopyruvate, a PDH complex inhibitor, reduces the current density [22] . Together with our observations, the literature [22] supports the hypothesis that the downregulation of Kv channels underlies reduced K + currents in RVH and reflects transcriptional effects induced by PDK-mediated metabolic changes.
Limitations We realize that our data on the metabolic shift and electrical remodeling in RVH is only one step towards a better understanding of the pathophysiology in RVH and RV failure. The initiating stimulus for PDK activation is uncertain. However, since these changes occur only when the experimental RVH is severe, we speculate that it reflects a supply-demand mismatch in coronary perfusion of the nase kinase (PDK) in RVH reduces the coupling of glycolysis to glucose oxidation. These metabolic changes are (in part) rapidly reversible by dichloroacetate, which improves contractility by restoring normal RV energetics. PDK activation also inhibits the expression of Kv channels, which prolongs action potential duration (APD). Prolonged APD may also contribute to impairment of RV function in RVH RV and its increased metabolic demands. Consistent with this, several papers suggest that the hypertrophied RV may be ischemic [2, 35] . Future studies are required to determine the mechanism by which inhibition of PDH downregulates expression of the repolarizing Kv channels. Additional studies are also planned to assess other metabolic therapies in RVH, including agents that alter fatty acid oxidation, such as trimetazidine.
Although dichloroacetate has been safely used in humans to treat lactic acidosis related to mitochondrial diseases [36] , the long-term safety of dichloroacetate in patients with RVH remains to be determined. Moreover, the safety of drugs that reduce hypertrophy, traditionally thought to be a beneficial compensatory mechanism in conditions of increased afterload, remains to be established. In the case of dichloroacetate, we believe the fact that reduction in RVH relates to positive changes in vascular remodeling, and myocardial energetics favors the interpretation that regression of RVH reflects disease regression and is thus "beneficial".
While we found that alpha actin protein did not increase in RVH, Bakerman et al. noted an increase in alpha-skeletal actin mRNA in the RV of calves exposed to acute hypoxia [37] . While an RVH-associated increase in the reporter protein is a theoretical concern and could have complicated interpretation of the GLUT immunoblot, no increase in actin was observed. The differences between Bakerman's study and ours include the species and model of RVH used and the fact we measured protein while they measured mRNA. Changes in mRNA do not always translate into changes in protein. Finally Zhang et al., also using a rodent model, found no change in actin expression in a monocrotaline rodent model [7] .
Conclusion Electrical remodeling and RV dysfunction in RVH due to PAH and PAB relate to a glycolytic shift mediated, in large part, by PDK activation and inhibition of the PDH complex. Dichloroacetate reverses the electrical remodeling and enhances RV function by enhancing glucose oxidation (Fig. 8d) . The relevance of these findings is enhanced by the fact that dichloroacetate has been safely and chronically administered in humans [36] , suggesting a trial in RVH associated with PAH or pulmonic stenosis could be safely conducted.
